Skip to main content

Advertisement

SpringerLink
Log in

Metabolic components and recurrence in early-stage cervical cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Epidemiological evidence suggests that the metabolic syndrome (MetS) is associated with increased risk of cervical cancer. However, research on the impact of MetS on prognosis in cervical cancer is lacking. This study investigated the association between MetS and recurrence-free survival (RFS) in patients with early-stage cervical cancer. This is a retrospective study of patients diagnosed with the International Federation of Gynecology and Obstetrics (FIGO) stage I-II cervical cancer in three tertiary hospitals during 2006–2009. Cox proportional hazards model was used to estimate the association between MetS or MetS components and RFS. We were able to evaluate MetS status in 84 patients out of 127. Forty patients had MetS. RFS was not significantly different according to MetS status; however, there was no further event of recurrence in non-MetS group after 2 years from primary surgical treatment. Hypertriglyceridemia (HR 3.67, 95 % CI 1.18–11.43) and impaired fasting glucose (HR 4.30, 95 % CI 1.23–15.03) were independent risk factors for shorter RFS, after adjustment for age, lymph node involvement, tumor involvement of resection margin, parametrial invasion, FIGO stage at diagnosis, and adjuvant treatment. Hypertriglyceridemia and impaired fasting glucose were associated with higher risk of recurrence in patients with early-stage cervical cancer. Prospective validation in large populations and further studies on the impact of MetS treatment in patients with cervical cancer are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Gray HJ. Primary management of early-stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy. J National Compr Cancer Netw : JNCCN. 2008;6(1):47–52.

    Google Scholar 

  3. Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 2007;107(2):310–5. doi:10.1016/j.ygyno.2007.06.026.

    Article  PubMed  Google Scholar 

  4. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. doi:10.1161/CIRCULATIONAHA.105.169404.

    Article  PubMed  Google Scholar 

  5. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke. 2005;36(7):1366–71. doi:10.1161/01.STR.0000169945.75911.33.

    Article  CAS  PubMed  Google Scholar 

  6. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50. doi:10.1161/01.CIR.0000140677.20606.0E.

    Article  PubMed  Google Scholar 

  7. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006;169(5):1505–22. doi:10.2353/ajpath.2006.051090.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ulmer H, Bjorge T, Concin H, Lukanova A, Manjer J, Hallmans G, et al. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecol Oncol. 2012;125(2):330–5. doi:10.1016/j.ygyno.2012.01.052.

    Article  CAS  PubMed  Google Scholar 

  9. Penaranda EK, Shokar N, Ortiz M. Relationship between metabolic syndrome and history of cervical cancer among a US national population. ISRN Oncol. 2013;2013:840964. doi:10.1155/2013/840964.

    PubMed  PubMed Central  Google Scholar 

  10. Lacey Jr JV, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003;98(4):814–21. doi:10.1002/cncr.11567.

    Article  PubMed  Google Scholar 

  11. Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension. 2012;59(4):802–10. doi:10.1161/HYPERTENSIONAHA.111.189258.

    Article  CAS  PubMed  Google Scholar 

  12. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237–52.

    PubMed  Google Scholar 

  13. McTiernan A, Irwin M, Vongruenigen V. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(26):4074–80. doi:10.1200/JCO.2010.27.9752.

    Article  Google Scholar 

  14. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol, Biomark Prev : Publ Am Assoc Cancer Res, Cosponsored by Am Soc Prev Oncol. 1997;6(11):863–73.

    CAS  Google Scholar 

  15. Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer. 2009;101(7):1202–6. doi:10.1038/sj.bjc.6605264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sowers MR, Randolph Jr J, Jannausch M, Lasley B, Jackson E, McConnell D. Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the "timing hypothesis". Arch Intern Med. 2008;168(19):2146–53. doi:10.1001/archinte.168.19.2146.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer. 2001;84(3):417–22. doi:10.1054/bjoc.2000.1582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;91(13):1147–54.

    Article  CAS  PubMed  Google Scholar 

  19. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA : J Am Med Assoc. 2005;293(2):194–202. doi:10.1001/jama.293.2.194.

    Article  CAS  Google Scholar 

  20. Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol. 1992;136(9):1110–4.

    Article  CAS  PubMed  Google Scholar 

  21. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89(18):1360–5.

    Article  CAS  PubMed  Google Scholar 

  22. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 2011;60(10):1363–71. doi:10.1016/j.metabol.2010.09.012.

    Article  CAS  PubMed  Google Scholar 

  23. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010;15(6):548–55. doi:10.1634/theoncologist. 2009-0300.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, Selmer R, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009;6(12):e1000201. doi:10.1371/journal.pmed.1000201.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res. 1996;56(8):1761–5.

    CAS  PubMed  Google Scholar 

  26. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol : Off J Am Soc Clin Oncol. 2002;20(1):42–51.

    Article  CAS  Google Scholar 

  27. Huang YF, Shen MR, Hsu KF, Cheng YM, Chou CY. Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br J Cancer. 2008;99(7):1096–102. doi:10.1038/sj.bjc.6604661.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ursin G, Pike MC, Preston-Martin S, 3rd d'Ablaing G, Peters RK. Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case–control study (California, United States). Cancer Causes Control : CCC. 1996;7(3):391–401.

    Article  CAS  PubMed  Google Scholar 

  29. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. doi:10.1056/NEJMoa021423.

    Article  PubMed  Google Scholar 

  30. Key TJ, Allen NE, Verkasalo PK, Banks E. Energy balance and cancer: the role of sex hormones. Proc Nutr Soc. 2001;60(1):81–9.

    Article  CAS  PubMed  Google Scholar 

  31. Louwman WJ, Aarts MJ, Houterman S, van Lenthe FJ, Coebergh JW, Janssen-Heijnen ML. A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer. 2010;103(11):1742–8. doi:10.1038/sj.bjc.6605949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea

    Hee Kyung Ahn

  2. Department of Obstetrics and Gynecology, Gachon University Gil Medical Center, Incheon, Republic of Korea

    Jin Woo Shin & Chan-Yong Park

  3. Department of Statistics, Dongguk University, Seoul, Republic of Korea

    Hong Yup Ahn

  4. Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Republic of Korea

    Nak Woo Lee & Jae Kwan Lee

  5. Department of Family Medicine, Gachon University Gil Medical Center, 1198 Guwol-dong, Namdong-gu, Incheon, 405-760, Republic of Korea

    In Cheol Hwang

Authors
  1. Hee Kyung Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin Woo Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Yup Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chan-Yong Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nak Woo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jae Kwan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. In Cheol Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to In Cheol Hwang.

Additional information

Hee Kyung Ahn and Jin Woo Shin contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahn, H.K., Shin, J.W., Ahn, H.Y. et al. Metabolic components and recurrence in early-stage cervical cancer. Tumor Biol. 36, 2201–2207 (2015). https://doi.org/10.1007/s13277-014-2831-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2831-y

Keywords

Search

Navigation